Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.19
ELAN's Cash-to-Debt is ranked lower than
99.99% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. ELAN: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
ELAN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: No Debt Max: No Debt
Current: 0.19
0.19
No Debt
Equity-to-Asset 0.58
ELAN's Equity-to-Asset is ranked lower than
99.99% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ELAN: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
ELAN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.58  Med: 0.87 Max: 0.87
Current: 0.58
0.58
0.87
Debt-to-Equity 0.48
ELAN's Debt-to-Equity is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. ELAN: 0.48 )
Ranked among companies with meaningful Debt-to-Equity only.
ELAN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.48  Med: 0.48 Max: 0.48
Current: 0.48
Debt-to-EBITDA 5.62
ELAN's Debt-to-EBITDA is ranked lower than
99.99% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. ELAN: 5.62 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ELAN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 5.62  Med: 5.62 Max: 5.62
Current: 5.62
Interest Coverage 14.94
ELAN's Interest Coverage is ranked lower than
99.99% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. ELAN: 14.94 )
Ranked among companies with meaningful Interest Coverage only.
ELAN' s Interest Coverage Range Over the Past 10 Years
Min: 10.6  Med: No Debt Max: No Debt
Current: 14.94
10.6
No Debt
Altman Z-Score: 2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 10.23
ELAN's Operating Margin % is ranked lower than
99.99% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. ELAN: 10.23 )
Ranked among companies with meaningful Operating Margin % only.
ELAN' s Operating Margin % Range Over the Past 10 Years
Min: 0.19  Med: 7.33 Max: 10.23
Current: 10.23
0.19
10.23
Net Margin % 2.82
ELAN's Net Margin % is ranked lower than
99.99% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. ELAN: 2.82 )
Ranked among companies with meaningful Net Margin % only.
ELAN' s Net Margin % Range Over the Past 10 Years
Min: -10.75  Med: -4.45 Max: 2.82
Current: 2.82
-10.75
2.82
ROE % 0.87
ELAN's ROE % is ranked lower than
99.99% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. ELAN: 0.87 )
Ranked among companies with meaningful ROE % only.
ELAN' s ROE % Range Over the Past 10 Years
Min: -4.2  Med: -1.36 Max: 1.33
Current: 0.87
-4.2
1.33
ROA % 1.21
ELAN's ROA % is ranked lower than
99.99% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. ELAN: 1.21 )
Ranked among companies with meaningful ROA % only.
ELAN' s ROA % Range Over the Past 10 Years
Min: -3.65  Med: -1.18 Max: 1.21
Current: 1.21
-3.65
1.21
ROC (Joel Greenblatt) % 8.92
ELAN's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. ELAN: 8.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ELAN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.21  Med: -2.54 Max: 8.92
Current: 8.92
-12.21
8.92
3-Year Revenue Growth Rate 6.20
ELAN's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ELAN: 6.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ELAN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 6.2  Med: 6.2 Max: 6.2
Current: 6.2
3-Year EBITDA Growth Rate 27.30
ELAN's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. ELAN: 27.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ELAN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 27.3  Med: 27.3 Max: 27.3
Current: 27.3
GuruFocus has detected 1 Warning Sign with Elanco Animal Health Inc ELAN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ELAN's 30-Y Financials

Financials (Next Earnings Date: 2019-04-30)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ELAN Guru Trades in

ELAN Guru Trades in

Q3 2018

ELAN Guru Trades in Q3 2018

Vanguard Health Care Fund 901,500 sh (New)
PRIMECAP Management 3,750,000 sh (New)
Philippe Laffont 32,500 sh (New)
Andreas Halvorsen 652,140 sh (New)
Pioneer Investments 5,000 sh (New)
Ron Baron 10,000 sh (New)
George Soros 505,000 sh (New)
Steven Cohen 446,118 sh (New)
Dodge & Cox 2,012,033 sh (New)
Signature Select Canadian Fund 15,778 sh (New)
» More
Q4 2018

ELAN Guru Trades in Q4 2018

Eaton Vance Worldwide Health Sciences Fund 80,975 sh (New)
Paul Tudor Jones 12,938 sh (New)
Vanguard Health Care Fund 1,049,792 sh (+16.45%)
PRIMECAP Management 4,962,199 sh (+32.33%)
Pioneer Investments 5,766,978 sh (+115239.56%)
Andreas Halvorsen Sold Out
Philippe Laffont Sold Out
Dodge & Cox Sold Out
George Soros Sold Out
Steven Cohen 344,000 sh (-22.89%)
Ron Baron 9,505 sh (-4.95%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:ELAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare: » details
Traded in other countries:5EA.Germany,
Headquarter Location:USA


Top Ranked Articles about Elanco Animal Health Inc

Vanguard Health Care Fund Buys 4 Stocks in 3rd Quarter The fund’s largest new position is Elanco Animal Health
The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio last week, listing four new positions. Read more...

Ratios

vs
industry
vs
history
PE Ratio 193.32
ELAN's PE Ratio is ranked lower than
99.99% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. ELAN: 193.32 )
Ranked among companies with meaningful PE Ratio only.
ELAN' s PE Ratio Range Over the Past 10 Years
Min: 36.04  Med: 39.71 Max: 498.43
Current: 193.32
36.04
498.43
Forward PE Ratio 28.09
ELAN's Forward PE Ratio is ranked lower than
99.99% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. ELAN: 28.09 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 193.32
ELAN's PE Ratio without NRI is ranked lower than
99.99% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. ELAN: 193.32 )
Ranked among companies with meaningful PE Ratio without NRI only.
ELAN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 36.04  Med: 39.71 Max: 498.43
Current: 193.32
36.04
498.43
PB Ratio 2.17
ELAN's PB Ratio is ranked lower than
99.99% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. ELAN: 2.17 )
Ranked among companies with meaningful PB Ratio only.
ELAN' s PB Ratio Range Over the Past 10 Years
Min: 2.05  Med: 2.25 Max: 2.42
Current: 2.17
2.05
2.42
PS Ratio 4.84
ELAN's PS Ratio is ranked lower than
99.99% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ELAN: 4.84 )
Ranked among companies with meaningful PS Ratio only.
ELAN' s PS Ratio Range Over the Past 10 Years
Min: 4.58  Med: 5.01 Max: 5.53
Current: 4.84
4.58
5.53
Price-to-Free-Cash-Flow 27.03
ELAN's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. ELAN: 27.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ELAN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 25.52  Med: 28.12 Max: 37.64
Current: 27.03
25.52
37.64
Price-to-Operating-Cash-Flow 23.31
ELAN's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. ELAN: 23.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ELAN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 22  Med: 24.24 Max: 36.92
Current: 23.31
22
36.92
EV-to-EBIT 92.60
ELAN's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. ELAN: 92.60 )
Ranked among companies with meaningful EV-to-EBIT only.
ELAN' s EV-to-EBIT Range Over the Past 10 Years
Min: 58.2  Med: 88.75 Max: 99.3
Current: 92.6
58.2
99.3
EV-to-EBITDA 30.26
ELAN's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. ELAN: 30.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ELAN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 25.7  Med: 29 Max: 32.5
Current: 30.26
25.7
32.5
EV-to-Revenue 4.32
ELAN's EV-to-Revenue is ranked lower than
99.99% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. ELAN: 4.32 )
Ranked among companies with meaningful EV-to-Revenue only.
ELAN' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.1  Med: 4.5 Max: 5
Current: 4.32
4.1
5
Current Ratio 2.58
ELAN's Current Ratio is ranked lower than
99.99% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. ELAN: 2.58 )
Ranked among companies with meaningful Current Ratio only.
ELAN' s Current Ratio Range Over the Past 10 Years
Min: 2.58  Med: 3.15 Max: 3.3
Current: 2.58
2.58
3.3
Quick Ratio 1.55
ELAN's Quick Ratio is ranked lower than
99.99% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. ELAN: 1.55 )
Ranked among companies with meaningful Quick Ratio only.
ELAN' s Quick Ratio Range Over the Past 10 Years
Min: 1.55  Med: 1.65 Max: 1.73
Current: 1.55
1.55
1.73
Days Inventory 189.28
ELAN's Days Inventory is ranked lower than
99.99% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. ELAN: 189.28 )
Ranked among companies with meaningful Days Inventory only.
ELAN' s Days Inventory Range Over the Past 10 Years
Min: 113.41  Med: 236.74 Max: 239.62
Current: 189.28
113.41
239.62
Days Sales Outstanding 77.57
ELAN's Days Sales Outstanding is ranked lower than
99.99% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. ELAN: 77.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELAN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.69  Med: 73.29 Max: 77.57
Current: 77.57
71.69
77.57
Days Payable 47.59
ELAN's Days Payable is ranked lower than
99.99% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. ELAN: 47.59 )
Ranked among companies with meaningful Days Payable only.
ELAN' s Days Payable Range Over the Past 10 Years
Min: 47.59  Med: 49.79 Max: 59.11
Current: 47.59
47.59
59.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.90
ELAN's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. ELAN: -0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ELAN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.9  Med: -0.9 Max: -0.9
Current: -0.9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.97
ELAN's Price-to-Median-PS-Value is ranked lower than
99.99% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. ELAN: 0.97 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ELAN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.96  Med: 0.99 Max: 0.99
Current: 0.97
0.96
0.99
Earnings Yield (Greenblatt) % 1.08
ELAN's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. ELAN: 1.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ELAN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1  Med: 1.1 Max: 1.7
Current: 1.08
1
1.7

More Statistics

Revenue (TTM) (Mil) $3,066.80
EPS (TTM) $ 0.16
52-Week Range $28.00 - 37.61
Shares Outstanding (Mil)365.64

Analyst Estimate

Dec19 Dec20 Dec21
Revenue (Mil $) 3,146 3,214 3,319
EBIT (Mil $) 648 739 811
EBITDA (Mil $) 704 793 883
EPS ($) 1.07 1.30 1.45
EPS without NRI ($) 1.07 1.30 1.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.40%
Dividends per Share ($) 0.25 0.26 0.26

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}